|
| 37890146 | Differentiation of BCMA-specific induced pluripotent stem cells into rejuvenated CD8αβ+ T cells targeting multiple myeloma. | Blood | 2024 |
| 37890146 | Differentiation of BCMA-specific induced pluripotent stem cells into rejuvenated CD8αβ+ T cells targeting multiple myeloma. | Blood | 2024 |
| 35882498 | Improving NK cell function in multiple myeloma with NKTR-255, a novel polymer-conjugated human IL-15. | Blood Adv | 2023 |
| 35882498 | Improving NK cell function in multiple myeloma with NKTR-255, a novel polymer-conjugated human IL-15. | Blood Adv | 2023 |
| 36126301 | A MIR17HG-derived long noncoding RNA provides an essential chromatin scaffold for protein interaction and myeloma growth. | Blood | 2023 |
| 37608773 | Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma. | Haematologica | 2023 |
| 37680953 | Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment. | Cancer Res Commun | 2023 |
| 37611163 | Monoallelic deletion of BCMA is a frequent feature in multiple myeloma. | Blood Adv | 2023 |
| 36780189 | BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma. | Clin Cancer Res | 2023 |
| 37343562 | Studying the impact of translational genomic research: Lessons from eMERGE. | Am J Hum Genet | 2023 |
| 36826833 | Development of a Covalent Inhibitor of c-Jun N-Terminal Protein Kinase (JNK) 2/3 with Selectivity over JNK1. | J Med Chem | 2023 |
| 37464071 | Correction: UTX inactivation in germinal center B cells promotes the development of multiple myeloma with extramedullary disease. | Leukemia | 2023 |
| 37023227 | A pandemic preparedness network for individuals living with compromised immune systems. | Blood Adv | 2023 |
| 37021929 | Impact of bortezomib-based versus lenalidomide maintenance therapy on outcomes of patients with high-risk multiple myeloma. | Cancer | 2023 |
| 37463058 | Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401. | Clin Cancer Res | 2023 |
| 37198323 | UTX inactivation in germinal center B cells promotes the development of multiple myeloma with extramedullary disease. | Leukemia | 2023 |
| 37071725 | Familial Hypercholesterolemia in the Electronic Medical Records and Genomics Network: Prevalence, Penetrance, Cardiovascular Risk, and Outcomes After Return of Results. | Circ Genom Precis Med | 2023 |
| 36877894 | CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma. | Blood | 2023 |
| 36877894 | CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma. | Blood | 2023 |
| 36752202 | Heterogeneity of B cell lymphopoiesis in patients with premalignant and active myeloma. | JCI Insight | 2023 |
| 36631435 | Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma. | Blood Cancer J | 2023 |
| 36630605 | Ubiquitin receptor PSMD4/Rpn10 is a novel therapeutic target in multiple myeloma. | Blood | 2023 |
| 36746923 | Correction: Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma. | Blood Cancer J | 2023 |
| 36737429 | Identification of disease-related aberrantly spliced transcripts in myeloma and strategies to target these alterations by RNA-based therapeutics. | Blood Cancer J | 2023 |
| 37173587 | Determinants of response and resistance to T cell-engaging therapies in multiple myeloma. | Nat Rev Clin Oncol | 2023 |
| 37173155 | Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom's macroglobulinemia on diagnostic and response criteria. | Semin Hematol | 2023 |
| 36603186 | High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma. | Blood | 2023 |
| 36533670 | Dysfunctions of innate and adaptive immune tumor microenvironment in Waldenström macroglobulinemia. | Int J Cancer | 2023 |
| 37166811 | Compound Heterozygous LTBP2 Mutations Associated With Juvenile-Onset Open-Angle Glaucoma and Marfan-Like Phenotype. | JAMA Ophthalmol | 2023 |
| 37164047 | Multicenter clinical and functional evidence reclassifies a recurrent noncanonical filamin C splice-altering variant. | Heart Rhythm | 2023 |
| 36982699 | Transcriptome Analysis of Diffuse Large B-Cell Lymphoma Cells Inducibly Expressing MyD88 L265P Mutation Identifies Upregulated CD44, LGALS3, NFKBIZ, and BATF as Downstream Targets of Oncogenic NF-κB Signaling. | Int J Mol Sci | 2023 |
| 37528088 | Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel. | Blood Cancer J | 2023 |
| 37421589 | Characterizing dry mass and volume changes in human multiple myeloma cells upon treatment with proteotoxic and genotoxic drugs. | Clin Exp Med | 2023 |
| 37099031 | Report of consensus panel 7 from the 11th international workshop on Waldenström macroglobulinemia on priorities for novel clinical trials. | Semin Hematol | 2023 |
| 37528088 | Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel. | Blood Cancer J | 2023 |
| 37611163 | Monoallelic deletion of BCMA is a frequent feature in multiple myeloma. | Blood Adv | 2023 |
| 37608773 | Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma. | Haematologica | 2023 |
| 37680953 | Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment. | Cancer Res Commun | 2023 |
| 37023227 | A pandemic preparedness network for individuals living with compromised immune systems. | Blood Adv | 2023 |
| 37021929 | Impact of bortezomib-based versus lenalidomide maintenance therapy on outcomes of patients with high-risk multiple myeloma. | Cancer | 2023 |
| 37421589 | Characterizing dry mass and volume changes in human multiple myeloma cells upon treatment with proteotoxic and genotoxic drugs. | Clin Exp Med | 2023 |
| 36982699 | Transcriptome Analysis of Diffuse Large B-Cell Lymphoma Cells Inducibly Expressing MyD88 L265P Mutation Identifies Upregulated CD44, LGALS3, NFKBIZ, and BATF as Downstream Targets of Oncogenic NF-κB Signaling. | Int J Mol Sci | 2023 |
| 37343562 | Studying the impact of translational genomic research: Lessons from eMERGE. | Am J Hum Genet | 2023 |
| 37173587 | Determinants of response and resistance to T cell-engaging therapies in multiple myeloma. | Nat Rev Clin Oncol | 2023 |
| 37173155 | Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom's macroglobulinemia on diagnostic and response criteria. | Semin Hematol | 2023 |
| 37071725 | Familial Hypercholesterolemia in the Electronic Medical Records and Genomics Network: Prevalence, Penetrance, Cardiovascular Risk, and Outcomes After Return of Results. | Circ Genom Precis Med | 2023 |
| 37464071 | Correction: UTX inactivation in germinal center B cells promotes the development of multiple myeloma with extramedullary disease. | Leukemia | 2023 |
| 37166811 | Compound Heterozygous LTBP2 Mutations Associated With Juvenile-Onset Open-Angle Glaucoma and Marfan-Like Phenotype. | JAMA Ophthalmol | 2023 |
| 37099031 | Report of consensus panel 7 from the 11th international workshop on Waldenström macroglobulinemia on priorities for novel clinical trials. | Semin Hematol | 2023 |
| 37198323 | UTX inactivation in germinal center B cells promotes the development of multiple myeloma with extramedullary disease. | Leukemia | 2023 |